Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 15;77(12):1626-1634.
doi: 10.1093/cid/ciad460.

Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice

Essy Mozaffari  1 , Aastha Chandak  2 , Robert L Gottlieb  3   4   5   6 , Chidinma Chima-Melton  7 , Stephanie H Read  8 , Heng Jiang  9 , Mel Chiang  1 , EunYoung Lee  1 , Rikisha Gupta  1 , Mark Berry  1 , Andre C Kalil  10
Affiliations

Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice

Essy Mozaffari et al. Clin Infect Dis. .

Abstract

Background: Immunocompromised patients are at high risk of severe coronavirus disease 2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients hospitalized for COVID-19 reflect variations in clinical practice. In this comparative effectiveness study, we investigated the effect of remdesivir treatment on inpatient mortality among immunocompromised patients hospitalized for COVID-19 across all variants of concern (VOC) periods.

Methods: Data for immunocompromised patients hospitalized for COVID-19 between December 2020 and April 2022 were extracted from the US PINC AITM Healthcare Database. Patients who received remdesivir within 2 days of hospitalization were matched 1:1 using propensity score matching to patients who did not receive remdesivir. Additional matching criteria included admission month, age group, and hospital. Cox proportional hazards models were used to examine the effect of remdesivir on risk of 14- and 28-day mortality during VOC periods.

Results: A total of 19 184 remdesivir patients were matched to 11 213 non-remdesivir patients. Overall, 11.1% and 17.7% of remdesivir patients died within 14 and 28 days, respectively, compared with 15.4% and 22.4% of non-remdesivir patients. Remdesivir was associated with a reduction in mortality at 14 (hazard ratio [HR], 0.70; 95% confidence interval, .62-.78) and 28 days (HR, 0.75; 95% CI, .68-.83). The survival benefit remained significant during the pre-Delta, Delta, and Omicron periods.

Conclusions: Prompt initiation of remdesivir in immunocompromised patients hospitalized for COVID-19 is associated with significant survival benefit across all variant waves. These findings provide much-needed evidence relating to the effectiveness of a foundational treatment for hospitalized COVID-19 patients among a high-risk population.

Keywords: COVID-19; comparative effectiveness research; immunocompromised; mortality; remdesivir.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. E. M., E. L., R. G., M. C., and M. B. report employment and being stockholders with Gilead Sciences during the conduct of the study. A. C., S. H. R., and H. J. report funding for study and medical writing provided to their institution (Certara) from Gilead Sciences during the conduct of the study. R. L. G reports serving on scientific advisory boards for AbbVie, Eli Lilly, Gilead Sciences, GSK, Roche, Johnson & Johnson (coronavirus disease 2019 [COVID-19]–related randomized clinical trial, coordinating principal investigator), and Kinevant Sciences (academic steering committee, study investigator; fees to Baylor Scott & White Research Institute); serving as a consultant for Gilead Sciences (honoraria for lectures), Johnson & Johnson, and Kinevant Sciences (through his institution); serving on a speaker bureau for Pfizer unrelated to COVID-19; his institution received a gift-in-kind from Gilead Sciences to facilitate a multicenter clinical trial outside the scope of COVID-19; a de minimis investment in AbCellera; grants or contracts as a study investigator (fees to Baylor Scott & White Research Institute) from Regeneron, Eli Lilly, Gilead, Pfizer, JNJ, and Roivant Sciences (Kinevant Sciences); and receipt of travel support for original scientific presentations from Gilead Sciences. C. C.-M. reports payment or honoraria for lectures/speaker from AstraZeneca and participation on advisory board for Gilead Sciences. A. C. K. reports grants from the National Institutes of Health Adaptive COVID-19 Treatment Trial. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Graphical Abstract
Graphical Abstract
This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/remdesivir-reduced-mortality-in-immunocompromised-patients-hospitalized-for-covid-19-across-variant-waves-findings-from-routine-clinical-practice
Figure 1.
Figure 1.
Study population. Abbreviations: COVID-19, coronavirus disease 2019; LFO, low-flow oxygen.
Figure 2.
Figure 2.
Kaplan–Meier curves for time to mortality among immunocompromised patients across the coronavirus disease 2019 variant periods. “Days after baseline” refers to the time during which outcomes were assessed following the 2-day period in which remdesivir treatment administration was identified (baseline).
Figure 3.
Figure 3.
14-day and 28-day mortality among immunocompromised patients across the coronavirus disease 2019 variant periods (adjusted Cox proportional hazards model). Immunocompromised conditions included cancer, solid organ and hematopoietic stem cell transplant, hematologic malignancies, moderate or severe primary immunodeficiencies, immunosuppressive medications, asplenia, bone marrow failure/aplastic anemia, human immunodeficiency virus, and toxic effects of antineoplastics. Estimates adjusted for age, admission month, hospital ward on admission (intensive care unit vs general ward), and baseline treatments (anticoagulants, convalescent plasma, corticosteroids, baricitinib, tocilizumab). Abbreviations: CI, confidence interval; HR, hazard ratio.
See this image and copyright information in PMC

References

    1. Ao G, Wang Y, Qi X, et al. . The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis. Transplant Rev (Orlando) 2021; 35:100628. - PMC - PubMed
    1. MacKenna B, Kennedy NA, Mehrkar A, et al. . Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol 2022; 4:e490–506. - PMC - PubMed
    1. Song Q, Bates B, Shao YR, et al. . Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative. J Clin Oncol 2022; 40:1414–27. - PMC - PubMed
    1. Vijenthira A, Gong IY, Fox TA, et al. . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 2020; 136:2881–92. - PMC - PubMed
    1. Ferdinands JM, Rao S, Dixon BE, et al. . Waning of vaccine effectiveness against moderate and severe COVID-19 among adults in the US from the VISION network: test negative, case-control study. BMJ 2022; 379:e072141. - PMC - PubMed

Publication types

Grants and funding